semiglutide

Search documents
Novo Nordisk’s Canadian drug patent lapses, opening market for Hims & Her Health
CNBC Television· 2025-07-09 15:50
The company Hims and Hers trying to cash in on a Novo Nordisk mistake north of the border. Our Brandon Gomez joins us on set with those details. Hey Brandon. Hey Leslie.Yes. Look, a $450 mistake that opened floodgates to a billion dollar weight loss market in Canada. Let's get into it.Novo Nordis will lose its exclusive patent on semiglutide, its top selling drug OMIC and WGOi in Canada next January. Why. because someone in the company didn't pay a $450 licensing fee on time.The patent could have lasted unt ...